Human Cell Expression Systems for Authentic Recombinant Protein Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant human proteins often result in proteins that lack authenticity due to inadequate glycosylation patterns and incorrect folding, leading to reduced biological activity and increased immunogenicity, and are limited by the inability to express certain proteins like TGFβ1, which are notoriously difficult to produce in non-human cell systems.
Innovation Solution
The development of novel expression cassettes and vectors that utilize human-specific regulatory elements such as cytomegalovirus enhancer elements, human promoters, globin gene introns, and signal peptides to produce authentic recombinant human proteins in stable human cell lines, ensuring correct glycosylation and folding, and the use of serum-free media for high-yield, scalable production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If non-human cell systems are used to produce recombinant human proteins, then production efficiency and scalability are improved, but protein authenticity (glycosylation patterns and folding) deteriorates
Solution Approach 1:
The patent changes the fundamental parameter of host cell species from non-human to human, enabling the expression system to produce proteins with authentic human glycosylation patterns and folding while maintaining scalable production capabilities through engineered human cell lines
Solution Approach 2:
The patent introduces human-specific regulatory elements (promoters, enhancers, introns) as intermediaries between the recombinant gene and the expression machinery, ensuring that human proteins are produced with correct post-translational modifications while leveraging the robust production capabilities of engineered human cell systems
2Manufacturing precision
If human cell expression systems are used to produce authentic human proteins, then protein authenticity and biological activity are improved, but production complexity and scalability deteriorate
Solution Approach 1:
The patent segments the expression system into distinct functional modules: human-specific regulatory elements for authenticity, engineered cell line infrastructure for scalability, and optimized culture conditions, allowing each component to be independently optimized and combined
Solution Approach 2:
The patent creates universal human cell expression platforms that can produce multiple different human proteins with authentic characteristics, making the system broadly applicable across different therapeutic protein candidates while maintaining standardized production protocols
3Ease of manufacture
If conventional expression vectors are used in human cell lines, then ease of transfection is improved, but expression stability and protein yield deteriorate
Solution Approach 1:
The patent performs preliminary engineering of human cell lines to establish stable expression capabilities before protein production, pre-configuring the cellular machinery with appropriate promoters, enhancers, and regulatory elements to ensure high-yield authentic protein expression from the outset
Data Source
AI summary
The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.